Market Context — Why This Technology, Why Now

The global healthcare sector is rapidly shifting towards precision medicine and non-invasive diagnostics, driven by an aging population and the increasing prevalence of chronic inflammatory diseases. Regulatory bodies are also pushing for more accurate and earlier diagnostic tools to improve patient outcomes and reduce long-term care costs. This technology aligns perfectly with these trends, offering a competitive edge in a market demanding highly specific and sensitive diagnostic solutions for complex conditions like Ulcerative Colitis and PSC.

Key Competitive Advantages
01

Enables early, high-precision diagnosis of Ulcerative Colitis, differentiating it from other inflammatory bowel diseases with high sensitivity and specificity.

02

Provides a molecular biological foundation for personalized medicine by detecting integrin αVβ6/αVβ3 antibodies, capturing deeper insights into disease pathology.

03

Establishes strong patent protection, differentiating it from 10 cited prior art documents and securing a competitive market advantage.

Market Opportunity
Digestive Disease Diagnostic Market
$300M–$350M domestically (AI est.)
An increase in inflammatory bowel disease patients and rising demand for more precise diagnostic technologies are driving market expansion.
Major pharmaceutical companies Diagnostic kit manufacturers Clinical laboratory service providers
Personalized Medicine & Biomarker Market
$1.5B–$2.5B globally (AI est.)
The shift towards precision medicine tailored to individual patient conditions is advancing, increasing the importance of biomarkers that link diagnosis and treatment.
Biotech firms specializing in precision medicine Pharmaceutical R&D divisions CROs focused on biomarker discovery
Healthcare IoT Collaboration Services
$150M–$250M domestically (AI est.)
Integration with preventive medicine and disease management services is expected through digital management of non-invasive test data and application to telemedicine.
Digital health platform developers Telemedicine providers Health data analytics companies
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a broad scope of claims across 14 distinct points, covering the types of antibodies, samples, and detection methods for Ulcerative Colitis and PSC. Its patentability was established after overcoming rigorous examination and citing 10 prior art documents, indicating a robust and difficult-to-invalidate intellectual property with clear differentiation from existing technologies.

Competitive White Space

This patent focuses on diagnostic methods. White space exists in developing novel therapeutic agents targeting these integrins, or integrating this diagnostic into a broader digital health platform for chronic disease management.

Economic Impact
~$1.0M/year estimated medical cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Misdiagnosis or delayed diagnosis of Ulcerative Colitis increases complication risks and prolongs hospitalization, escalating medical costs. If 1,000 patients annually transition to early treatment due to this technology's high-precision diagnosis, an estimated ~$1,000/patient/year medical cost reduction (e.g., complication prevention, shorter hospital stays) is expected, leading to an annual reduction of ~$1.0M (AI est.).

Speed to Market
5× faster than in-house development
This technology has established biomarker identification and detection principles, with prior licensing success, significantly shortening the R&D phase. Adopting companies can reduce time and costs associated with basic research and clinical validation, focusing instead on product development. Leveraging existing diagnostic development expertise, early market entry is anticipated, potentially saving approximately 4 years compared to in-house development from scratch.
Competitive Positioning

X: Diagnostic Accuracy and Specificity
Y: Patient Burden Reduction

Business Models & Applications
🔬 Diagnostic Kit Sales
Develop and sell In Vitro Diagnostic (IVD) kits utilizing this technology to healthcare institutions. Monetize as a high-precision early diagnostic tool.
🧪 Testing Service Provision
Offer specialized testing services by receiving samples from medical institutions and performing analyses using this technology. Generate revenue by providing comprehensive diagnostic reports.
💊 Pharmaceutical Development Support
Provide this technology as a companion diagnostic for new therapeutic drugs. Utilize it for target patient selection and treatment efficacy monitoring, monetizing through partnerships with pharmaceutical companies.
Adjacent Application Opportunities
🔬 Drug Discovery & Clinical Development
Biomarker in Clinical Trials
This technology could serve as a crucial biomarker for patient selection and treatment efficacy monitoring in clinical trials for Ulcerative Colitis therapies. This application has the potential to enhance drug effectiveness and contribute to reducing development timelines by up to 20%.
🍎 Preventive Medicine & Healthcare
Screening for At-Risk Populations
The technology could be offered as a regular screening test for individuals with risk factors for Ulcerative Colitis. Early detection and intervention may prevent severe progression in up to 30% of cases, contributing to reduced hospitalization and overall healthcare costs.
🧬 Regenerative Medicine & Cell Therapy
Treatment Efficacy Marker
This could be applied as an objective marker to assess the efficacy of regenerative medicine and cell therapies for inflammatory bowel diseases. It may provide quantifiable data on cell engraftment and tissue repair, potentially improving treatment success rates by 15-20%.
Integration Roadmap — Estimated 24-Month Deployment
Technology Validation & Prototype Development
Duration: 6 months
Conduct principle validation of the patented technology, optimize the detection system, and develop an initial prototype. Evaluate integration potential with existing immunoassay equipment and identify technical challenges.
Clinical Performance Evaluation & Demonstration Test
Duration: 12 months
Perform performance evaluation using clinical samples in collaboration with medical institutions. Verify sensitivity and specificity, confirm differentiation capabilities from other diseases, and collect data for regulatory approval.
Productization & Market Introduction
Duration: 6 months
Pursue regulatory approval as an in vitro diagnostic (IVD) medical device, establish manufacturing lines, and build sales channels. Initiate deployment to target medical institutions to penetrate the market.
Technical Feasibility
This technology detects antibodies immunologically in samples, making maximum use of common immunoassay equipment and technical infrastructure, such as ELISA and immunostaining, prevalent in existing clinical laboratories. Minimal new specialized equipment investment is required, and integration into existing testing workflows is straightforward, indicating a low technical adoption barrier.
Success Scenario
Implementing this technology could enable non-invasive, high-precision detection of early-stage Ulcerative Colitis lesions often missed by conventional methods. This may allow patients to receive appropriate early treatment, potentially suppressing disease progression and significantly improving long-term quality of life. For healthcare providers, faster and more accurate diagnoses are expected to enhance patient satisfaction and treatment efficiency.
Patent Record
APPLICATION NO.
特願2020-563877
REGISTRATION NO.
7317379
FILING DATE
2019/12/27
GRANT DATE
2023/07/21
EXPIRATION DATE
2039/12/27
PATENT HOLDER
国立大学法人京都大学
Examination History
2022年07月21日
出願審査請求書
2023年03月28日
拒絶理由通知書
2023年05月24日
手続補正書（自発・内容）
2023年05月24日
意見書
2023年06月27日
特許査定